Therefore, the goal of this study was to demonstrate the PD-1 and PD-L2 expression rate of various hematologic malignancies and to evaluate whether PD-1 and PD-L2 expressions have an impact on prognosis. This evidence concerns the gene PDCD1LG2 and hematologic disorder.